| 查看: 865 | 回复: 2 | ||
| 当前只显示满足指定条件的回帖，点击这里查看本话题的所有回帖 | ||
小木虫刘树青木虫 (著名写手)
夜未眠
|
[求助]
求大神翻译 只有一段哦,谢谢
|
|
|
In the future, it is likely that ctDNA and CTCs will have complementary roles as cancer biomarkers although separate approaches may have distinct advantages in specificclinicalcontexts. ctDNA analysis is appealing due to the ease with which plasma can be collected and analyzed without the prior need to enrich and isolate a rare population of cells. For this reason, ctDNA analysis is likely to be the preferred option for genotyping and monitoring treatment response. The analysis of ctDNA can be applied as a high-throughput strategy for the assessment of clinical samples, but is limited to the analysis of point mutations, structural rearrangements, copy number aberrations and changes in DNA methylation. In contrast, the analysis of CTCs provides the unique opportunity to study the whole cell, allowing DNA, RNA and protein-based molecular profiling, and the opportunity for functional studies to guide personalized treatment selection. Although the analysis of both ctDNA and CTCs pose several technical challenges, ongoing improvements are expected over coming years, and both approaches hold great promise as biomarkers in various facets of cancer management. Technological advances might allow in the future, the use of a liquid biopsy (CTCs or ctDNA) for earlier cancer diagnosis or detection of disease relapse/progression. However, it is not known if earlier detection will lead to improved patient outcomes. This will become possible only if effective treatments are available to target early recurrences. Another open question is whether the liquid biopsy will complement analysis of primary tumor or metastases for tailoring treatment selection. Ongoing interventional clinical trials using CTC detection and characterization by CellSearch® will provide initial answers on the above question. Future research will be focused on optimizing and standardizing new technologies for both ctDNA and CTC analysis, demonstrating appropriate analytical and clinical validity as well as establishing the clinical utility of ctDNA and CTC testing through appropriately designed prospective clinical trials. |
回复此楼» 猜你喜欢
071000生物学调剂求助
已经有14人回复
-
材料调剂
已经有9人回复
-
277求调剂
已经有19人回复
-
344求调剂
已经有6人回复
-
化工调剂求导师收留！一志愿失利，踏实肯干，有植物提取科研经历
已经有13人回复
-
一志愿西交机械专硕求调剂
已经有4人回复
-
277 数一104，学硕，求调剂
已经有14人回复
-
求调剂 材料与工程 324分 专硕
已经有17人回复
-
342电子信息专硕求调剂
已经有4人回复
-
0835学硕299求调剂 08大类可接受
已经有7人回复
3楼2016-03-29 07:58:13
追梦青年LWQ
金虫 (正式写手)
- 应助: 0 (幼儿园)
- 金币: 1096.3
- 散金: 444
- 红花: 2
- 帖子: 355
- 在线: 45.7小时
- 虫号: 3688586
- 注册: 2015-02-14
- 专业: 机械工程
2楼2016-03-27 08:02:21
